TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

TG Therapeutics, Inc.NASDAQ: TGTX

Deferred Revenue · Q3 FY2026 · quarter ended Sep 2026

Deferred revenue broadly unchanged from a year ago

Deferred revenue stood at $26.1M at the end of Q3 FY2026, down 1.1% from a year earlier and up 55.1% from the prior quarter.

Context

  • Deferred revenue amounted to 1.6% of total assets at the end of Q3 FY2026, down 0.9 pp from a year earlier.
  • Deferred revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -1.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$26.1M+55.1% QoQ
Last fiscal yearDec 2025
$21.23M+86.0% YoY
Year agoSep 2025
$26.4M-1.1% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.1%——
1 year+86.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
21.23M USD
Year-over-year change
+86.0%

Deferred Revenue vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1.1% is the lowest of 4, against a peer median of +335.3%.
  • Deferred revenue amounts to 1.6% of total assets for TGTX, versus a peer median of 0.1%.
TGTX Competitors
Deferred Revenue for TGTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$67.99M USD+335.3%+3.0%31.2%
TGTXTG Therapeutics, Inc.Sep 2026$26.1M USD-1.1%—1.6%
GMABGenmab A/SJun 2026$21M USD+250.1%—0.2%
ADAGAdagene Inc.Dec 2025$3.46M USD—-38.8%4.4%
IPHAInnate Pharma S.A.Dec 2025€2.82M EUR+358.4%-24.5%4.5%
XNCRXencor, Inc.Jun 2026$0 USD——0.0%
CLDXCelldex Therapeutics, Inc.Sep 2026$0 USD——0.0%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
ADCTADC Therapeutics S.A.Mar 2026$0 USD——0.0%
Peer median (excluding TGTX) —+335.3%-24.5%0.1%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents298.89M102.3M92.93M179.89M79.15M
Short-term Investments15.88M59.37M124.58M131.11M62.82M
Net Receivables1.39M051.09M129.19M305.63M
Inventory0039.82M110.46M125.59M
Other Current Assets2.88M2.36M5.34M15.72M57.58M
Total Current Assets330.97M168.27M317.94M566.36M630.76M
Property, Plant & Equipment (Net)11.07M10.82M8.15M7.15M6.28M
Goodwill799K799K799K00
Intangible Assets00000
Long-term Investments35.53M12.4M1.29M808K59.14M
Tax Assets0000348M
Other Non-current Assets1.26M1.27M1.42M3.37M19.08M
Total Non-current Assets48.66M25.3M11.64M11.33M432.49M
Total Assets379.63M193.57M329.59M577.69M1.06B
Account Payables0000107.51M
Short-term Debt975K0001.04M
Tax Payables00000
Deferred Revenue00152K11.41M21.23M
Other Current Liabilities62.97M51.62M52.12M78.11M23.97M
Total Current Liabilities65.38M53.2M53.72M90.68M153.76M
Long-term Debt66.79M71.14M100.12M244.43M252.67M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)457K305K6.02M12.09M8.81M
Other Non-current Liabilities0000(7.02M)
Total Non-current Liabilities77.09M81.78M115.37M264.65M261.47M
Total Liabilities142.48M134.99M169.09M355.33M415.23M
Common Stock143K146K151K156K159K
Retained Earnings(1.33B)(1.53B)(1.55B)(1.53B)(1.08B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity237.15M58.59M160.5M222.36M648.02M
Total Debt79.05M83.06M110.8M253.72M260.73M
Net Debt(219.84M)(19.24M)17.86M73.83M181.58M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.